Oncolytic viruses (OV) have broad potential as an adjuvant for the treatment of solid tumors. The present study addresses the feasibility of clinically applicable drugs to enhance the oncolytic potential of the OV Delta24-RGD in glioblastoma. In total, 446 drugs were screened for their viral sensitizing properties in glioblastoma stem-like cells (GSCs) in vitro. Validation was done for 10 drugs to determine synergy based on the Chou Talalay assay. Mechanistic studies were undertaken to assess viability, replication efficacy, viral infection enhancement and cell death pathway induction in a selected panel of drugs. Four viral sensitizers (fluphenazine, indirubin, lofepramine and ranolazine) were demonstrated to reproducibly synergize with Delta24-RGD in multiple assays. After validation, we underscored general applicability by testing candidate drugs in a broader context of a panel of different GSCs, various solid tumor models and multiple OVs. Overall, this study identified four viral sensitizers, which synergize with Delta24-RGD and two other strains of OVs. The viral sensitizers interact with infection, replication and cell death pathways to enhance efficacy of the OV.
INTRODUCTION
Patients newly diagnosed with glioblastoma have a median survival of 14.7 months despite surgery and radiation combined with adjuvant chemotherapy using temozolomide. 1, 2 Hence, studies into more effective alternatives are warranted. An approach that is currently under phase-I/II clinical investigation is the use of the oncolytic adenovirus Delta24-RGD. 3 Treatment with Delta24-RGD has shown promising results in preclinical models 4 and has demonstrated therapeutic responses in a subset of patients. 3 This is similar to results of other oncolytic virus (OV) trials. 5 Delta24-RGD was engineered to specifically target and replicate in cancer cells deficient in the Rb pathway by means of a 24-base pair deletion in the viral E1A gene. Insertion of the RGD-peptide into the fiber knob enhances viral entry by attachment to αvβ3/αvβ5 integrins. 6 Delta24-RGD is, therefore, not dependent on the entry via the coxsackie adenovirus receptor (CAR), which is usually sparsely expressed in glioblastoma. 7 In OV therapy, heterogeneous responses have been shown both in preclinical models as well as in patients. 3, 8, 9 Therefore, such treatment strategies require enhancement of OV efficacy in order to be potentially curative. This can be achieved by enhancing replication, attenuating cellular defense mechanisms to infection, enhancing viral lysis or altering the immune response.
The current study is aimed at the identification of sensitizers of oncolysis mediated by Delta24-RGD using the National Institutes of Health clinical collection. 10 One of the advantages of this drug library is the favorable toxicity profile of the drugs as these agents are routinely prescribed for a wide spectrum of clinical indications. Also, the pharmacological properties are known for most of these agents. These factors make these drugs suitable for rapid translation into clinical trials after in vitro confirmation. Potential heterogeneity in response to the newly identified combination therapies was studied utilizing a well-characterized panel of patient-derived glioblastoma stem-like cell cultures (GSCs). 11, 12 This model is known to preserve the original phenotypic and genotypic tumor characteristics. 11, 12 We characterize the identified viral sensitizers with regard to important aspects in glioblastoma treatment, including synergistic interactions and viral mechanistic enhancement such as viral infectivity, viral protein production, viral gene expression and viral replication. Moreover, we study the cellular induction of apoptosis and necrosis.
In addition, we present data on the general applicability of the identified drugs as viral sensitizers in other types of neoplasms and in combination with other types of OVs. The effects of Delta24-RGD are also enhanced by the identified viral sensitizers in triple-negative breast cancer, ovarian carcinoma and colon carcinoma. Finally, the identified viral sensitizers enhanced the efficacy of both the Herpes Simplex Virus (HSV)-1-based OV G47Δmcherry, 13 as well as the wildtype oncolytic Newcastle disease virus (NDV), 14 in the GSC model.
RESULTS
GSCs demonstrate heterogeneous susceptibility to Delta24-RGD The therapeutic efficacy of Delta24-RGD is heterogeneous between glioblastoma patients. 3, 9 Therefore, investigations into potential viral sensitizers should be designed to yield insights both from responsive and resistant models. To achieve this, we screened eight GSCs for their responsiveness to Delta24-RGD. The non-replicating vector Ad.Luc.RGD was used to assess infectivity and the results show substantial variation between the eight GSCs ( Figure 1a ). GS79 was relatively resistant, whereas GS359 was very sensitive to adenoviral infection. The remaining cultures GS401, GS245 GS184, GS102, GS281 and GS295 were intermediately sensitive.
Next, the viral protein production of Delta24-RGD during the first replication cycle was determined by staining for the adenoviral capsid protein hexon ( Figure 1b ) at 48 h. The number of hexon counts at this time point revealed a similar pattern to the luciferase expression data of Figure 1a , with the most resistant GS79 having the lowest hexon counts and the most sensitive GS359 having the highest counts.
Two cultures were selected for the subsequent drug screen to investigate which drugs sensitize glioblastoma to OV therapy with Delta24-RGD. Based on the infection and viral protein production assays, GS79 was picked as the 'resistant' sample and GS102 as the 'intermediate resistant' sample. Accordingly, the IC 50 values of Delta24-RGD in GS79 and GS102 were found to be high compared with the multiplicity of infection (MOI) observed in conventional cell lines 8 ; MOI200 for GS79 and MOI70 for GS102 ( Figures 1c  and d ).
Clinical drug screening identifies potential sensitizers of OV therapy with Delta24-RGD In order to identify viral sensitizers of OV therapy with Delta24-RGD in GSCs, the National Institutes of Health clinical collection was explored (Supplementary Figure S1a 10 ). This collection contains 446 drugs most of which have been approved by the Food and Drug Administration for use in humans for a wide spectrum of clinical indications. 15 A third of these are central nervous system drugs, including anti-epileptics, antidepressants and antipsychotics. The drug screening strategy is illustrated in a flow-chart (Supplementary Figure S1b ). The primary screen was performed on the two mentioned cultures GS79 and GS102 at a drug concentration of 100 μM. Potential viral sensitizers were defined as described in the materials and methods section, which resulted in two arms. The first arm consisted of 332 drugs for which monotherapy reduced viability between 25 and 75%. Of those drugs, six had viral sensitizing effects in both GS79 and GS120. The second arm consisted of drugs for which monotherapy at 100 μM decreased GSC viability by 475% (n = 114 drugs), which is incompatible with a reliable evaluation of additive effects with Delta24-RGD. Therefore, these drugs were titrated for combination therapy activity at 50, 10, 5 or 1 μM, which resulted in the identification of four viral sensitizers with enhancement effect at a dosage of 10 or 5 μM. In total, 10 drugs had a viral sensitizing effect in both GSCs. Table 1 provides an overview of these drugs which are; amlodipine, anagrelide, ebselen, fenoldopam, fluphenazine, indirubin, lofepramine, ranolazine, stiripentol and sumatriptan succinate.
Synergy was detected for six of the potential viral sensitizers The 10 identified viral sensitizers were validated and tested for synergistic activity in GS79 cells according to the Chou-Talalay methods. 16 The IC 50 values were determined by concentrationresponse assays (displayed in Table 1 ). The combination assays were performed and the combination indices were calculated. Four of the 10 identified drugs were synergistic (combination index o 1) and 2 were additive (combination index = 1) when combined with Delta24-RGD. These were anagralide, ebselen, fluphenazine, indirubin, lofepramine and ranolazine (Figures 2a and b, Table 1 ). The other drugs (amlodipine, fenoldopam, stiripentol and sumatriptan) failed to reproduce enhancement in This table shows the 'hits' that were selected for validation. The combinations of these drugs with Delta24-RGD were more effective than virus alone in both GS79 and GS102 cells at the indicated concentrations (column 2-4). The molecular weight of the agent is indicated (column 5), and the drug category and therapeutic indication are provided (columns 6 and 7). The results are shown of the absolute difference in viability between single and combination treatment as well as the enhancement factor of the combination therapy in the two GSC cultures (columns [8] [9] [10] [11] . The results of the validation experiments in GS79 are provided in columns 9-13. The IC 50 values of the drugs are depicted in column 12. The outcome of the Chou Talalay analysis (synergy, additivity or antagonism) is provided in column 13. Results of a literature search for blood-brain barrier penetration of the drugs is listed in column 14.
the wider concentration range of in vitro testing and were therefore excluded from further validation. In addition, the literature was searched for the ability of the six drugs to cross the blood-brain barrier in vivo. [17] [18] [19] [20] [21] Anagrelide was excluded from further studies because it has not been reported to penetrate the blood-brain barrier in vivo (Table 1) , whereas this has been reported for the other drugs.
Viral sensitizers increase adenoviral infection and replication efficacy
To determine whether the drugs improved the efficacy of viral infection, the luciferase expression of the Ad.Luc.RGD-infected sensitizers ( Figure 3b ). Both indirubin and lofepramine were demonstrated to influence the adenoviral receptor expression at 4 and 8 h post-treatment. We did not find upregulation of entry receptors by fluphenazine, although the viral infectivity was increased as shown in Figures 3a. For ranolazine, no effects on the surface receptors were observed. In summary, fluphenazine, indirubin and lofepramine increased viral infection. For lofepramine and indirubin this was associated with increased levels of CAR and slightly increased levels of αvβ3 integrins.
Effects of the drugs on Delta24-RGD early viral replication, late viral gene expression and progeny production We investigated the Delta24-RGD-induced viral hexon production during the first viral cycle as a measure of replication efficacy after combination therapy with the viral sensitizers. At MOI 60, the four drugs increased the number of hexon spots at 48 h (Po 0.05). Ebselen slightly decreased the number of hexon counts per well (P o 0.01). Fluphenazine, lofepramine and ranolazine all increased viral protein production by two-to threefold and indirubin was most effective, increasing the hexon counts by 3.7-fold (Po 0.01). At the higher virus concentration of MOI 125, only indirubin and ranolazine were still significantly increased compared with control ( Figure 3c ).
To measure the effects of the four drugs on the viral cycle in a longitudinal manner, we performed time-lapse fluorescence imaging of Delta24-RGD-green fluorescent protein (GFP)-infected cells. GFP is expressed late in the replication cycle ( Figure 3d ). Indirubin, ranolazine and fluphenazine peaked earlier than controls suggesting more efficient replication and lysis. The GFP data were in line with the results of the hexon staining. Both indirubin and ranolazine enhanced Delta24-RGD-GFP expression (P o 0.01 and Po 0.001, respectively). Differences in the kinetics were observed, namely indirubin increased peak levels of GFP expression whereas ranolazine increased the fluorescence levels consistently over time without evidently enhancing peak levels. In accordance with the previous findings, ebselen reduced viral replication of Delta24-RGD-GFP (P o0.05). Due to the pronounced inhibitory effects of ebselen in both the viral infection and replication assays this drug was not further evaluated.
To assess whether the enhancement of early and late viral protein production translates to increased viral progeny production, viral titration assays were performed ( Figure 3e ). Only indirubin increased the viral progeny production in GS79 cells at both 48 and 96 h post-infection from 5.2 × 10 4 to 6.7 × 10 4 (P o 0.05) and from 5.9 × 10 4 to 9.0 × 10 4 (P o 0.05), respectively, compared with Delta24-RGD alone. Interestingly, fluphenazine and ranolozine achieved the opposite effect from indirubin: a decrease in viral progeny production at both time points (P o 0.05). Lofepramine did not significantly alter the viral progeny production. In summary, the viral progeny production was increased by indirubin and was decreased by both fluphenazine and ranolazine.
The viral sensitizers increase Delta24-RGD-induced oncolysis by enhancing apoptosis and necrosis
We performed an in silico analysis using the Ingenuity Pathway Analysis (IPA; September 2014) software (Supplementary Figure  S2) to identify which pathways are activated or inhibited by the four viral sensitizers. Next, we evaluated whether identified cell death pathways are relevant for viral oncolysis. Fluphenazine targets the dopamine receptor, indirubin targets the aryl hydrocarbon receptor and the apoptotic signaling molecules Bcl-2, BIRC5 and NFκB, lofepramine affects pro-apoptosisassociated SMPD1 and ranolazine affects the adrenergic receptor. The top 10 of overlapping functions of the downstream molecules of these drugs included relevant mechanisms for viral oncolysis such as cell death, apoptosis and necrosis.
Others have found cell death pathways to be affected by OV therapy. 22, 23 As oncolysis induced by the adenovirus is reported to be associated with both apoptosis and necrosis, we investigated the role of the viral sensitizers in both cellular responses. A longitudinal assessment of caspase 3/7 activity was performed to study the role of the viral sensitizers on apoptosis. All four viral sensitizers induced caspase 3/7 activity at early time points posttreatment ( Figure 4a ). Infection with Delta24-RGD led to a delayed onset of caspase 3/7 activity. Combination treatments of Delta24-RGD with each of the four viral sensitizers also led to a delayed onset of caspase 3/7 expression but with a higher peak activity level for indirubin at 9-15 h and prolonged higher caspase 3/7 activity for fluphenazine, lofepramine and ranolazine at 30-60 h (P o 0.05).
To determine necrotic cell death, a lactate dehydrogenase (LDH) assay was used. This assay measures the release of LDH in the culture medium, which serves as a dynamic marker for loss of cellular membrane integrity, an early event in necrotic cell death. (Figure 4b ). Delta24-RGD (MOI 75) monotherapy increased LDH levels 5 days post-infection (P o 0.05 compared with controls). Fluphenazine was the only viral sensitizer that increased LDH levels in combination with the virus compared with both single agents (P o 0.05). Indirubin and lofepramine combined with the virus increased LDH levels compared with the drugs alone, whereas ranolazine increased LDH compared with the virus alone (P o 0.05). In conclusion, viral sensitizers combined with Delta24-RGD effectively induced both apoptotic and necrotic cell death in vitro. The four drugs interacted with apoptotic cell death as derived from caspase 3/7 activity. Enhanced necrosis was demonstrated using ranolazine and fluphenazine.
Viral sensitizers are effective in a broad panel of heterogeneously responding patient-derived GSCs Glioblastoma is a heterogeneous tumor, which has profound consequences for efficacy of therapeutics. To place the viral sensitizing ability of the four drugs in the context of this molecular heterogeneity, a broader panel of GSCs was employed to investigate their general applicability. Table 2 shows the molecular characteristics of the panel of GSC cultures indicating that all The Cancer Genome Atlas-defined subtypes are represented, as well as both methylated and unmethylated MGMT promoter subtypes. The viral sensitizers were combined with Delta24-RGD in the GSCs that were used in the initial infectivity studies (Figures 1a and b ) and expanded with an additional set amounting to a total of 12 GSC cultures. The four viral sensitizers were applied in two different concentrations in combination with two MOIs of Delta24-RGD (Figures 5a and d) . Enhancement was considered significant if the combination therapy decreased the viability compared with both single agents therapies (P o 0.05). Fluphenazine was effective in enhancing Delta24-RGD oncolysis in all 12 patientderived GSCs. Indirubin was effective in 11/12 GSCs. Lofepramine was effective in 9/12 cultures mainly at the higher concentration of 20 μM and ranolazine was effective in 11/12 cultures. Overall, these data confirm that the four drugs that were identified as potential viral enhancers by a screen on GS79 are effective in a broader panel of patient-derived GSCs, which bear distinct molecular characteristics and show differential sensitivity to Delta24-RGD. These findings suggest that the identified sensitizers could be effective in enhancing Delta24-RGD oncolytic therapy in a broader context of heterogeneous glioblastomas.
General applicability of the drugs: enhancement in other tumor cell lines and enhancement of other viruses The applicability of the four drugs as viral sensitizers was subsequently investigated in a broader perspective. We tested the combination of Delta24-RGD and the viral sensitizers in other tumor cell lines, namely the breast carcinoma cell line MB-MDA-231, the ovarian cancer cell line SKOV3 and the colon carcinoma cell line HCT-116 (Figure 6a ; Supplementary Figures  S3-S4 ). Chou-Talalay assays were performed to determine synergy, additivity or antagonism. The results reveal that fluphenazine, indirubin and ranolazine show synergy in all three cell lines, however, there are large differences in the actual enhancement. Lofepramine showed additive enhancement in HCT-116 and synergy in SKOV3 and MB-MDA-231 cell lines. Ranolazine showed synergy at low concentrations in SKOV3 cells, at high concentrations in MB-MDA-231 cells and at all concentrations in HCT-116 cells. In summary, the four drugs, and in particular, ranolazine and indirubin, are effective sensitizers of Delta24-RGD in other tumor cell lines including those originating from triple negative breast carcinoma, colon carcinoma and ovarian carcinoma. The extent of the enhancement could be tumor type dependent. In addition, we assessed the sensitizing effects of the four compounds on two other OVs, the NDV and the HSV-based G47Δ-mcherry in GS79 and GS102 (Figure 6b ; Supplementary Figure S4 ). The results show that fluphenazine, indirubin and lofepramine effectively synergized with G47Δmcherry in both GSCs. All four drugs were effective in combination with NDV, where ranolazine was the least effective drug. Also, the extent of the enhancement depended on both the virus and the cell culture. In summary, fluphenazine, indirubin and lofepramine are effective viral sensitizers for the OVs based on NDV and HSV vectors.
DISCUSSION
The present study has identified four clinically approved viral sensitizers for the oncolytic adenovirus Delta24-RGD in patientderived GSCs, namely fluphenazine, indirubin, lofepramine and ranolazine. Mechanistic studies attributed the synergistic activity with the virus partly to enhanced infection, replication or both. Not in the least, the induction of programmed cell death through apoptosis and or necrosis, was found to be increased and accelerated. As such, we conclude that these four viral sensitizers are potentially promising adjuvants to virotherapy for glioblastoma.
Previously, we have reported the strength of implementing a panel of GSCs for the assessment of combination therapy for glioblastoma in vitro. 9, [24] [25] [26] The National Institutes of Health clinical compound library has been applied to GSCs before, 27, 28 which resulted in the identification of numerous GSC specific compounds, and established the use of GSCs as a useful tool for drug screening experiments. Interestingly, Pollard et al., identified fluphenazine as a monotherapeutic agent in three GSC cultures as well. We performed the first systematic drug screen to identify clinically approved drugs that enhance oncolytic adenovirus potency. Others have identified synergizing compounds in a mechanism driven strategy, 29, 30 or by combining the current clinical standard therapeutics [31] [32] [33] and radiation therapy. 4, 34, 35 Compound screenings for oncolytic HSV, myxoma and vesicular stomatitis virus have been reported using other chemical libraries. [36] [37] [38] The strategy to detect viral sensitizers through high throughput screening, as implemented in this study, results in the unbiased detection of very potent Food and Drug Administrationapproved compounds.
One of the advantages of screening panels of GSCs is the identification of responders and non-responders, which grants the opportunity to investigate underlying mechanisms. 25 Accordingly we have observed that the response to Delta24-RGD therapy is heterogeneous 8 , and may be driven by cell-entry receptors, autophagy mediated lysis and cellular anti-viral response. 22, 39, 40 Viral sensitization by these four compounds was reproduced in a panel of twelve GSCs, which suggests applicability of combination therapy in both intrinsically resistant and susceptible glioblastoma patients. Furthermore, viral sensitizing by the four drugs was not restricted to Delta24-RGD; both NDV and HSV virotherapy synergized with these compounds, nor was is restricted to glioblastoma, as viral sensitizing was observed in cell lines derived from other tumors. These results suggest that a more general mechanism of action underlies these combination therapies.
The combination of the in vitro drug screen and the in silico pathway analysis on the identified compounds was shown to be a powerful tool to predict mechanisms of action. As indicated by the in silico analysis, the four compounds converge on cell death pathway enhancement, which we could substantiate in the validation experiments. The pathways identified were of specific interest for combination treatment with Delta24-RGD, as apoptosis and necrosis have been shown to be involved in oncolytic cell death. [41] [42] [43] The identified viral sensitizers have been sparsely investigated in the context of OV therapy. Below, we discuss the four viral sensitizers individually with regard to the mechanism of action, the reported effects in combination with viruses and their known effects on the immune response. The immune response is crucial for Delta24-RGD efficacy in vivo. 44 Fluphenazine is a neuroleptic drug used for the treatment of psychosis and has not been previously identified as a viral enhancer. The drug enhanced infection, viral protein synthesis as well as oncolysis in the whole panel of patient-derived GSC cultures. Interestingly the viral progeny yield was decreased, which may be related to the enhanced apoptotic and necrotic cell death possibly interfering with efficient viral particle production. Earlier, fluphenazine was reported to inhibit leukemia and brain tumor cells, 27, 45, 46 which may be related to the inhibition of calmodulin that contributes to apoptosis through caspase 8 activation and Akt-pathway inhibition. 47 Indirubin is used in Chinese medicine as an antipsoriatic 48 and anti-leukemia drug. 49 In OV therapy using Delta24-RGD, we showed that indirubin increases infection, CAR and integrin expression, viral protein production during the first cycle, viral gene expression over time and viral progeny production. Increased viral activity by indirubin has thus far not been reported. Indeed, indirubin derivatives have been shown to affect viral activities. Indirubin-3′-monoxime was effective in increasing viral transduction of an adeno-associated viral vector. 50 Another derivative was shown to inhibit viral replication of H5N1, 51 cytomegalovirus, 52 and the pseudorabies virus. 53 These reports and the results within this study, suggest that the effects of indirubin on viral replication may depend on the indirubinderivative used, and/or on type of virus investigated. In our study, indirubin consistently augmented adenoviral oncolysis in multiple GSC cultures and other cancer cell lines, as well as the oncolytic activity of two other viruses, NDV and HSV. The downstream molecules of indirubin are associated with apoptosis, 54 which was confirmed by our in vitro studies. Indirubins may also have specific effects on the immune system as indirubin-3'-monoxime has been reported to induce immunosuppressive and anti-inflammatory effects on dendritic cells. 55 Moreover, inhibition of the indirubin target GSK-3 reduces microglial inflammatory responses. 56 Additional studies are warranted to investigate the effects on the immune response by indirubin in combination with Delta24-RGD.
The anti-depressant lofepramine has not previously been identified as an enhancer of viral efficacy. We show that this drug increases viral infection, which was associated with upregulation of viral entry receptors, and enhances viral replication. The in silico pathway analysis revealed that lofepramine as a monotherapy affects downstream molecules related to apoptosis. This was translated to the combination therapy as well, as we confirmed in vitro. As a single drug treatment, lofepramine has been reported to block leukemia cell proliferation and to sensitize cells to apoptosis. 57 The anti-anginal drug ranolazine is a sodium-channel blocker that has not been studied in combination with OVs. Ranolazine enhanced the viral infection (culture specific) and viral protein production during the first viral cycle. However, viral progeny production was decreased, which is possibly related to enhanced induction of apoptosis and necrosis. Ranolazine has not been reported to possess direct tumor killing activity, however, a role for this drug in sodium channel-mediated breast cancer invasiveness has been reported. 58 The current study reveals novel mechanisms associated with this drug, which were not previously identified. Neither ranolazine nor lofepramine have been studied in the context of the immune system.
In conclusion, our study identified four effective viral sensitizers for Delta24-RGD oncolytic therapy in glioblastoma. These drugs include fluphenazine, indirubin, lofepramine and ranolazine. This study reveals the interaction of the drugs with important viral oncolytic cell death mechanisms, as shown in silico and in vitro. The identified drugs are not only applicable in glioblastoma but show synergy with Delta24-RGD in multiple cancer types. Moreover, all drugs except ranolazine act synergistically with other OVs as well. Although the identified viral sensitizers are clinically applicable, future studies should focus on finding the optimal administration to achieve maximal effects in vivo. GS79  CLA  UM  GS102  NEU  M  GS184  CLA  M  GS209  PRO  UM  GS245  NEU  UM  GS257  CLA  UM  GS281  MES  UM  GS295  MES  UM  GS335  CLA  M  GS357  CLA  M  GS359  MES  M  GS368  CLA  UM  GS401 PRO M Abbreviation: GSC, glioblastoma stem-like cell. Twelve patient-derived GSC cultures were used for the screening of the identified viral sensitizers in a larger panel. The culture used for the initial experiments (GS79) is also included in the table. The molecular characteristics are shown, including the molecular subtype according to The Cancer Genome Atlas (TCGA) and the MGMT promoter methylation status.
Clinical drugs enhance oncolytic virus Delta24-RGD Moreover, in vivo studies with these agents are required to interrogate their effects on the immune response to OV therapy, a factor known to have a pivotal role in therapeutic outcome of these therapies.
MATERIALS AND METHODS

Clinical drugs
The National Institutes of Health clinical collection which contains 446 drugs was obtained from the NCI/DTP Open Chemical Repository (http://dtp.cancer.gov). All drugs were dissolved in dimethylsulfoxide (DMSO) at 10 mM. For validation, the hereafter named drugs were purchased individually, dissolved in DMSO and stored at − 20°C. 
Viruses
The OV Delta24-RGD was used for the viability experiments and the titration experiments. This virus has been described previously 6 and includes both a 24-base pair deletion (E1A region) for selective replication in Rb-pathway deregulated tumor cells, and an RGD peptide insertion for cell binding and entry using αv integrins. 59 The replication-deficient adenoviral vector Ad.luc.RGD was used for assessment of infectivity and was kindly provided by Dr DT Curiel, (University of Alabama, Birmingham, AL, USA). The Delta24-RGD-GFP was constructed for monitoring viral replication using fluorescent imaging and contains a GFP expression cassette under the E3-promotor. This virus was produced, purified and titrated as previously described. 60 The NDV has been described previously. 14 The HSV-1 based OV G47Δ-mCherry was constructed as described previously. 13 Patient-derived serum-free cultured glioblastoma stem-like cells
The patient-derived GSCs used for the experiments included a panel of cultures that were established and maintained under serum-free conditions. The tumor specimens were acquired with patients' informed consent and with approval of the Institutional Review Board of the ErasmusMC. The fresh resection material was dissociated mechanically and enzymatically as described previously. 11 The applied method has been demonstrated to (1) retain genetic stability after passaging; 11, 61 (2) to recapitulate the phenotypic characteristics of the original tumor 11, 12 and (3) to preserve markers of stemness in glioblastoma cells. 62 The cells were maintained under serum-free conditions in Dulbecco's Modified Eagle Medium (DMEM)/F12 medium supplemented with 1% penicillin/streptomycin, 2% B27, 20 ng ml − 1 , basic fibroblast growth factor 20 ng ml − 1 , epidermal growth factor (Life Technologies, Paisley, UK), and 5 μg ml − 1 heparin (Sigma-Aldrich), at 37°C in a humid 95% air per 5% CO 2 chamber. The parental tumors and the cell cultures were molecularly characterized as has been described previously. 11 The GSCs were classified as glioma World Health Organization guidelines grade IV by histopathological assessment of the parental tumor. The passages used were between p8 and p22, derived from the Master Cell bank of the Erasmus MC Brain Tumor Repository, which are cell cultures that are molecularly characterized, show reproducible growth curves, are proven negative for mycoplasma and show full correspondence to the parental tumor from which it derived by short tandem repeat typing. As depicted in, Figure 1 we have selected both a resistant (GS79) and an averagely resistant GSC (GS102) for the initial drug screening. The panel for the validation of the four drugs was composed by selecting GSCs that were both resistant and sensitive to Delta24-RGD treatment as known from previous studies. We also included some additional GSCs that have effective proliferative properties.
Cell lines
The A549 lung adenocarcinoma cell line and SKOV3 ovarian carcinoma cells were obtained from ATCC (Manassas, VA, USA). The HCT-116 colon carcinoma cells were obtained from Sigma-Aldrich. The triple negative breast carcinoma cell lines MB-MDA-231 was kindly provided by K Naipal, MD, of the Department of Genetics, ErasmusMC, Rotterdam, The Netherlands. The cells were cultured in DMEM medium conditions with 10% fetal bovine serum and 1% penicillin/streptomycin. The cell lines were maintained at 37°C in a humid 95% air/5% CO 2 chamber.
Viability assays and screening method
Patient-derived GSCs and the cell lines of the other tumor types were seeded at 1 × 10 3 cells/well in 96-well plates. After 24 h of incubation the cells were treated with the drugs at a concentration of 100 μM, and combined with Delta24-RGD (MOI 50). Cell viability was measured using the CellTiter-Glo assay (Promega, Madison, WI, USA) after 5 days of incubation. For all drugs the combination drug effects were compared to single agent effects, with DMSO as controls. In cases where cell viability was reduced by more than 75% by the drug alone, the drug was rescreened at 10 and 1 μM. If the drug and the combination treatment did not affect viability in this screen ( o25% reduction of non-treated controls), that is, concentrations were too low, then the drug was tested in the third experiment at 50 and 5 μM). Potent viral sensitizers had to meet the criteria of (1) an enhancement factor (explained in the 'statistical analysis' section) of 42 in viability reduction in both of the tested GSCs, and an absolute enhancement of 425% in one the cultures, and (2) the viability of cells treated with the monotherapies had to be 425% compared with controls, as additional effects are difficult to distinguish below this threshold. After identification of the drugs that met these criteria, the drugs were further evaluated for available data on the bloodbrain barrier penetration. The validation of identified drugs was performed using the Chou-Talalay assays, to determine synergy between Delta24-RGD and the drugs by median effect equation calculation. 16 For the Chou-Talalay assay, the IC 50 values were determined via a concentration range of threefold steps, ensuring no effect on the one end, and complete cell kill on the other end of the concentration range. Similarly, combination effects were determined using a concentration range of the drug with a concentration range of the virus. Viability was measured by CellTiter-Glo (Promega). The assays were performed in triplicate using the glioblastoma culture GS79. The same cell culture as in the original drug screen was used for the Chou Talalay experiments. The combination index was calculated for every combination and considered synergistic if o1, additive if 1 and antagonistic if 41. The screen on a panel of GSCs was performed according to a same treatment regimen, by using two drug concentrations, namely the IC 50 value as Figure 6 . Drug/virus combination effects in different tumor cell lines and with different OVs. (a) Dose-response combination assays were performed using Chou-Talalay analysis to study interaction between Delta24-RGD and the four viral sensitizers in three tumor cell lines, being triple negative breast, ovarian and colon carcinoma cells. Viability was measured at day five post-treatment. The combination indices (CI) were calculated and are shown for the various treatment combinations in these cell lines. (b) Dose-response combination assays were performed using Chou-Talalay assays to study interaction between the four viral sensitizers and oncolytic HSV and NDV in the GSCs GS79 and GS102. Viability was measured at day five post-treatment. The combination indices (CI) are shown for the various treatment combinations in these cell lines.
determined in GS79 and a twofold step lower doses. Two MOIs of Delta24-RGD were used (MOI 25 and MOI 75). The results are presented as percentage of non-treated controls with standard error.
Viral infection assays
The effects of the selected drugs on viral infection were assessed using the non-replicating vector Ad.luc.RGD as described previously. 8 GS79 and GS102 cells were seeded at 5 × 10 3 cells/well in a 96-wells plate and kept overnight in an incubator. The cells were treated with one concentration of the four drugs and infected with Ad.Luc.RGD. Post-infection, the cells were incubated for 24 h and permeabilized by a freeze/thaw cycle in Triton X-100 (0.9% v/v). Steady-Glo substrate (Promega) was added and luciferase was measured with an Infinite M200 plate reader (Tecan, Männedorf, Switzerland). The results are presented from three independent experiments as percentage of Ad.Luc-RGD only treated cells with s.e.
Viral protein expression and viral titration assays by hexon staining
The viral protein expression in Delta-24RGD infected cells was determined by direct staining for viral hexon protein at 48 h post-infection of GS79 cells. The cells were seeded 1 × 10 3 cells per well in 96-well plates and after 24 h, the cells were treated with Delta24-RGD ( Figure 1 ) or with Delta24-RGD and one of the viral sensitizers (Figure 3 ). After 48 h cells were fixed with cold methanol and stained as described below. The results are displayed as mean counts/well of triplicates with s.d.
Viral titration assays were performed to determine progeny viral particle production. For this, GS79 cells were seeded at 5 × 10 4 cells per well and after 24 h were treated with Delta24-RGD in combination with each of the four drugs. At both 48 and 96 h the cells and supernatants were harvested. Three freeze-thaw cycles were performed, the cells were centrifuged at 1500 r.p.m. for 3 min to remove cell debris, and the supernatants were collected. Supernatants were added in serial dilution to 1 × 10 3 cells per well of the A549 lung adenocarcinoma cell line. At 48 h cells were fixed using ice-cold methanol and washed in phosphate-buffered saline/0.05% Tween-20 (Sigma-Aldrich). Staining was done using the primary mouse anti-hexon antibody in phosphate-buffered saline/1% bovine serum albumin (Adeno-X Rapid Titer Kit, #632250, Clontech, CA, USA). The hexon plaques were quantified and viral titers were calculated in triplicate. The results are shown as mean of the three viral titers and were considered significant if P o0.05 (using the Student's T-test) Late viral transgene expression using Delta24-RGD-GFP Late viral transgene expression was studied by evaluating GFP expression from a Delta24-RGD-GFP virus. GFP expression was monitored over time. GS79 cells were seeded at 2.5 × 10 3 cells per well in 96-well plates and were incubated with the identified drugs and/or Delta24-RGD-GFP at concentrations at which synergy had been detected by Chou-Talalay analysis. The plates were placed in an IncuCyte real-time cell imaging incubator (Essen BioScience, Hertfordshire, UK) and GFP was measured for 5 consecutive days. The experiment was performed in duplicate and fluorescence was measured every two hours and graphically displayed as mean object counts per mm 2 .
Flow cytometry on integrin αvβ3 and CAR expression GS79 cells were seeded at 5 × 10 4 cells per well in 6-well plates. After 24 h the cells were treated with fluphenazine, indirubin, lofepramine and ranolazine at the concentrations shown in the results. At 4, 8 and 24 h the cells were harvested, washed and incubated for 15 min in FACS buffer (phosphate-buffered saline/0.25%, bovine serum albumin/0.05%, NaN3-/0.5 mM, EDTA/2% human serum) using primary mouse anti-CD51/CD61 (1:50, Abcam (Cambridge, UK)) and primary rabbit anti-CAR (H-300, 1:50, Santa Cruz (Dallas, TX, USA)). After a washing step the cells were incubated with Alexa-488 anti-rabbit and PE-anti mouse secondary antibodies (Life Technologies). Next, the cells were fixed in BD FACS lysing buffer (BD Biosciences, CA, USA). In the flow cytometry analysis, a minimum of 3 × 10 4 events was obtained on a FACS Canto II (BD Bioscience). Flow cytometry data were analyzed by using the Infinicyt software (Cytognos, Salamanca, Spain), where debris and doublets were removed with FSC-H and FSC-A. The expression was plotted for the remaining events.
In silico analysis of pathways and target molecules
The IPA software was used for in silico analyses on the drugs of interest. We aimed to find mechanisms related to the efficacy of combination therapy, by analyzing downstream molecules influenced by the four drugs, fluphenazine, indirubin, lofepramine and ranolazine. We investigated overlapping functions of the four drugs to detect common pathways of interaction (IPA). Firstly, molecules of common pathways were identified for fluphenazine, indirubin, lofepramine and ranolazine by in silico connection using the 'build' algorithm and addition of downstream direct and indirect molecules. The results were projected in a network for the four drugs (Supplementary Figure S2) . Furthermore, the 'comparison analysis' in the IPA software was used to analyze common pathways of the four drugs and discover potential novel drugs with the same mechanism of action. The top 10 common pathways were considered significant if the P-value o0.05. The analysis was based on the first and second level of downstream affected molecules of the various drugs.
Caspase 3/7 activity
To evaluate Caspase 3/7 activity, cells were seeded 5 × 10 3 cells per well in a black-walled 96-well plate. The cells were treated with the four drugs as single treatment, virus alone, or in combination with Delta24-RGD, at a concentration at which synergy was observed in the Chou Talalay assays. Staurosporine (Sigma Aldrich, 20 nM) was used as a positive control. The CellPlayer 96-Well Kinetic Caspase 3/7 Apoptosis Assay (Essen BioScience) was added to the wells and, the caspase 3/7 activity was tracked by fluorescent images over a time period of 60 h with the IncuCyte system (Essen BioScience) using a 10 × magnification at 37°C. Two fluorescent images per well of triplicates were collected every two hours up to 60 h and displayed as object counts per mm 2 .
LDH assay GS79 cells were seeded at 1.0 × 10 3 cells per well in a 96-well plate. After 24 h, cells were incubated with two concentrations of the drugs fluphenazine, indirubin, lofepramine and ranolazine in the range at which synergy was detected and two concentrations of virus (MOI 100 and MOI 50). The cells were incubated for five days and placed at 37°C in a humidified 95% air per 5% CO 2 incubator. After this period, the amount of LDH in the supernatant was determined using the CytoTox-One assay (Promega). Fluorescence was measured in a Tecan Reader. Cell viability was measured by CellTiter-Glo assay to calculate the ratio of LDH per number of living cells. The results were presented as LDH per viable unit as percentage of non-treated controls with the s.e. The experiments were performed in triplicate.
Statistical analysis
The initial drug screens were performed in singlicate in two distinct GSCs and was validated by a second experiment using the Chou Talalay analysis to determine synergy. The validation experiments were performed in triplicate and was repeated if necessary, to ensure the IC 50 values of the two agents were combined by approximation, In the initial compound screens, the 'Enhancement' was calculated according to the description of Chou, 63 namely the viability of the most effective monotherapy divided by the viability of the combination therapy. The criterion for designating a drug as potential viral sensitizer was as follows: an enhancement of 42 in both tested cultures, and an absolute reduction of the single drug treatment with 425% viability in at least one culture. The 'Absolute Difference' is the viability of the most effective monotherapy minus the viability of the combination therapy, which determines the absolute reduction in viability of cells in the combination treatment compared to the single agent treatment. 63 The drug alone had to reduce viability by no more than 75% as below 25% viability combination effects are difficult to detect.
The Chou-Talalay method was performed as described 16 and means were plotted with standard deviations. To compare effects of different treatments, the Student's T-test was used, and statistical significance was reached if P o0.05. The caspase 3/7 activity was calculated as objects counts per well. The caspase 3/7 activity and Delta24-RGD-GFP over time were analyzed by a two-way analysis of variance with a Tukey's post-test. The treatment effect was compared with the controls, and combination treatments to both single agent treatments.
